USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
COLLABORATIVE DRUG DISCOVERY, INC.
Address:
1633 Bayshore Hwy, Suite 342
BURLINGAME, CA
Phone:
N/A
URL:
N/A
EIN:
142163157
DUNS:
149823846
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $299,996.00 2
SBIR Phase II $1,404,275.00 1
STTR Phase I $404,603.00 2
STTR Phase II $997,178.00 1

Award List:

Identification of novel therapeutics for tuberculosis combining cheminformatics,

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$149,382.00
Agency:
HHS
Principal Investigator:
Sean Ekins – 269-930-0974
Research Institution:
Sri International
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new… More

Biocomputation across distributed private datasets to enhance drug discovery

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$149,999.00
Agency:
HHS
Principal Investigator:
Barry A. Bunin – 650-219-4153
Abstract:
DESCRIPTION (provided by applicant): Collaborative Drug Discovery, Inc. (CDD) proposes to create a novel web-based software platform that enables scientists to work together effectively to discover and improve new drug leads, yet with the option not to reveal chemical structures to each other. It… More

Identification of novel therapeutics for tuberculosis combining cheminformatics,

Award Year / Program / Phase:
2012 / STTR / Phase II
Award Amount:
$997,178.00
Agency:
HHS
Principal Investigator:
Sean Ekins – 269-930-0974
Research Institution:
JOHNS HOPKINS UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): We are witnessing the growing menace of both increasing cases of drug-sensitive and drug-resistant Mycobacterium tuberculosis (Mtb) strains and the challenge to produce the first new tuberculosis (TB) drug in well over40 years. The TB community, having invested… More

Identification and Validation of Targets of Phenotypic High Throughput Screening

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$255,221.00
Agency:
HHS
Principal Investigator:
Sean Ekins – 215-687-1320
Research Institution:
SRI INTERNATIONAL
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease.… More

Modulation of the Innate Immune System by Fisetin for the Treatment of AD

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$149,997.00
Agency:
HHS
Principal Investigator:
Barry A. Bunin – 650-219-4153
Abstract:
DESCRIPTION (provided by applicant): Collaborative Drug Discovery, Inc. (CDD) proposes to create an innovative software module that will help biologists to quickly and easily encode their plain-text biological assay protocols into formats suitable for computational processing. The software will… More

Biocomputation across distributed private datasets to enhance drug discovery

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,404,275.00
Agency:
HHS
Principal Investigator:
Sean Ekins – 215-687-1320
Abstract:
DESCRIPTION: Collaborative Drug Discovery, Inc. (CDD) will create a novel web-based software platform that enables scientists to work together effectively to discover and improve new drug leads by sharing computational predictions based on open-source descriptors and models, for the first time… More